Oramed Pharmaceuticals Inc. (ORMP) P/E Ratio History
UndervaluedTrading at 3.0x vs 5Y avg 7.4x · 50th percentile · Below historical baseline · Data 2023–2026
Loading P/E history...
P/E Ratio Analysis
As of October 3, 2026, Oramed Pharmaceuticals Inc. (ORMP) trades at a price-to-earnings ratio of 3.0x, with a stock price of $4.49 and trailing twelve-month earnings per share of $4.11.
The current P/E is 60% below its 5-year average of 7.4x. Over the past five years, ORMP's P/E has ranged from a low of 1.2x to a high of 22.8x, placing the current valuation at the 50th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.2x, ORMP trades at a 87% discount to its sector peers. The sector includes 225 companies with P/E ratios ranging from 0.0x to 190.0x.
Relative to the broader market, ORMP trades at a notable discount to the S&P 500 median P/E of 24.5x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ORMP DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
ORMP Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
ORMP P/E vs Peers
Drug Delivery Technology Platforms peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $1B | 190.0 | - | -79% | |
| $166B | 10.8Lowest | 0.52Best | +2% | |
| $1.1T | 49.8 | 1.73 | +96% | |
| $96B | 11.1 | - | +46% | |
| $218B | 28.3 | 9.63 | +88% | |
| $125B | 17.7 | - | +178%Best | |
| $158B | 20.4 | - | -4% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
ORMP Historical P/E Data (2023–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q2 | - | $4.81 | $4.11 | 1.2x | -84% |
| FY2026 Q1 | - | $3.40 | $2.58 | 1.3x | -82% |
| FY2025 Q4 | Dec 31 2025 | $2.85 | $1.48 | 1.9x | -74% |
| FY2025 Q3 | - | $2.64 | $0.99 | 2.7x | -64% |
| FY2024 Q3 | Sep 30 2024 | $2.44 | $0.11 | 22.8x | +207% |
| FY2024 Q2 | Jun 30 2024 | $2.57 | $0.51 | 5.1x | -32% |
| FY2024 Q1 | Mar 31 2024 | $2.92 | $0.26 | 11.3x | +53% |
| FY2023 Q4 | Dec 31 2023 | $2.31 | $0.18 | 13.1x | +77% |
Average P/E for displayed period: 7.4x
ORMP Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
3+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ORMP — Frequently Asked Questions
Quick answers to the most common questions about buying ORMP stock.
What is ORMP's P/E ratio?
Oramed Pharmaceuticals Inc. (ORMP) trailing twelve-month P/E ratio is 3.0x, based on TTM diluted EPS of $4.11. The 5-year average P/E is 7.4x and the historical range spans 1.2x to 22.8x.
Is ORMP stock overvalued or undervalued?
ORMP trades at 3.0x P/E, below its 5-year average of 7.4x. At the 50th percentile of its historical range (1.2x–22.8x), the stock is priced at a discount to its own history.
Is ORMP stock expensive?
No, ORMP is not expensive on a historical basis. The current P/E of 3.0x is below the 5-year average of 7.4x and sits at the 50th percentile of its valuation range.
What is ORMP's historical P/E range?
Over the past 5 years, ORMP's P/E ratio has ranged from 1.2x to 22.8x, with a median of 5.1x and an average of 7.4x. The current P/E of 3.0x places the stock at the 50th percentile of this range. Full historical data spans 2023–2026.
How does ORMP's P/E compare to the S&P 500?
ORMP trades at 3.0x P/E versus the S&P 500 median of 24.5x. The 88% discount to the market suggests lower growth expectations or perceived higher risk.
How does ORMP's valuation compare to Healthcare peers?
Oramed Pharmaceuticals Inc. P/E of 3.0x compares to the Healthcare sector median of 23.2x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is ORMP's PEG ratio?
ORMP PEG ratio is N/A, based on a P/E of 3.0x and EPS growth of 419.1%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is ORMP's earnings yield?
ORMP earnings yield is 33.41%, the inverse of its 3.0x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.